- Chimeric Therapeutics (CHM) enters a strategic partnership with Oncobay Clinical to advance its clinical trials
- The company says the partnership will enable it to expand its CAR T therapy for treating patients with an aggressive type of brain or spine cancer
- The company says the partnership will enable the accelerated development of the CHM 1101 program
- Chimeric Therapeutics last traded at 32 cents on September 1
Chimeric Therapeutics (CHM) has entered a strategic partnership to advance its clinical trial.
The clinical-stage cell therapy company has teamed up with Oncobay Clinical to expand the clinical development program for CHM 1101. OncoBay Clinical is an immuno-oncology clinical research organisation specialising in rare and complex oncology indications including cellular therapies.
CHM 1101 is under evaluation in a single-site phase 1 clinical trial. CHM 1101 is a CAR T therapy for treating patients with Glioblastoma, an aggressive type of cancer.
The company says its new partnership will enable the expansion of the program to additional clinical trial sites and aggregate the data from all sites to prepare for the registration phase two program.
The expansion of this program will take place under Chimeric’s recent IND clearance from the FDA for CHM 1101.
Through the partnership, OncoBay Clinical will be able to leverage the support of its subsidiary, Moffitt Cancer Centre’s top scientific advisors, creating “vein-to-vein” control of cell therapy trials.
President and CEO of OncoBay Clinical Krystyna Kowalczyk said the company is excited by the new partnership.
“We are confident that our proven ability to succeed in managing the complexities of cell therapy research will enable the accelerated development of Chimeric’s CHM 1101 program,” said Krystyna Kowalczyk.
Chimeric Therapeutics last traded at 32 cents on September 1.